Literature DB >> 22440891

Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases.

Ashwin N Ananthakrishnan1, Emily L McGinley.   

Abstract

INTRODUCTION: Serious infections are an important side effect of immunosuppressive therapy used to treat Crohn's disease (CD) and ulcerative colitis (UC). There have been no nationally representative studies examining the spectrum of infection related hospitalizations in patients with IBD.
METHODS: Our study consisted of all adult CD and UC related hospitalizations from the Nationwide Inpatient Sample 2007, a national hospitalization database in the United States. We then identified all infection-related hospitalizations through codes for either the specific infections or disease processes (sepsis, pneumonia, etc.). Predictors of infections as well as the excess morbidity associated with infections were determined using multivariate regression models.
RESULTS: There were an estimated 67,221 hospitalizations related to infections in IBD patients, comprising 27.5% of all IBD hospitalizations. On multivariate analysis, infections were independently associated with age, co-morbidity, malnutrition, TPN, and bowel surgery. Infection-related hospitalizations had a four-fold greater mortality (OR 4.4, 95% CI 3.7-5.2). However, this varied by type of infection with the strongest effect seen for sepsis (OR 15.3, 95% CI 12.4-18.6), pneumonia (OR 3.6, 95% CI 2.9-4.5) and C. difficile (OR 3.2, 95% CI 2.6-4.0), and weaker effects for urinary infections (OR 1.4, 95%CI 1.1-1.7). Infections were also associated with an estimated 2.3 days excess hospital stay (95% CI 2.2-2.5) and $12,482 in hospitalization charges.
CONCLUSION: Infections account for significant morbidity and mortality in patients with IBD and disproportionately impact older IBD patients with greater co-morbidity. Pneumonia, sepsis and C difficile infection are associated with the greatest excess mortality risk.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22440891     DOI: 10.1016/j.crohns.2012.02.015

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  47 in total

1.  Risks of Infection among the Older Inflammatory Bowel Disease Patients.

Authors:  Christina Y Ha
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

2.  A Rare Case of Invasive Pancreatitis in an Immunocompromised Host.

Authors:  Diego Colom-Steele; Daniel Castresana; Joshua Hanson; Gulshan Parasher; Denis McCarthy
Journal:  Dig Dis Sci       Date:  2016-12       Impact factor: 3.199

3.  Fecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease.

Authors:  Robert J Gianotti; Alan C Moss
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-04

Review 4.  Clinical outcomes and management of inflammatory bowel disease in the older patient.

Authors:  Christina Y Ha; Seymour Katz
Journal:  Curr Gastroenterol Rep       Date:  2013-02

Review 5.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

Review 6.  Vaccination in the Elderly and IBD.

Authors:  Anthony J Choi; Preston Atteberry; Dana J Lukin
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

7.  Clinical assessment of risk factors for infection in inflammatory bowel disease patients.

Authors:  Joan Tosca; Natalia Garcia; Isabel Pascual; Marta Maia Bosca-Watts; Rosario Anton; Ana Sanahuja; Pilar Mas; Francisco Mora; Miguel Minguez
Journal:  Int J Colorectal Dis       Date:  2020-01-08       Impact factor: 2.571

8.  Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.

Authors:  A N Ananthakrishnan; A Cagan; T Cai; V S Gainer; S Y Shaw; S Churchill; E W Karlson; S N Murphy; I Kohane; K P Liao
Journal:  Aliment Pharmacol Ther       Date:  2015-04-13       Impact factor: 8.171

9.  Prevalence and incidence of antimicrobial-resistant organisms among hospitalized inflammatory bowel disease patients.

Authors:  Alon Vaisman; Kevin Pivovarov; Allison McGeer; Barbara Willey; Bjug Borgundvaag; Vanessa Porter; Piraveina Gnanasuntharam; Yanliang Wei; Geoffrey C Nguyen
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

10.  Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab.

Authors:  Andrada Seicean; Anca Moldovan-Pop; Radu Seicean
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.